Verrica Pharmaceuticals Stock Performance
| VRCA Stock | USD 0.52 0.04 7.14% |
The entity has a beta of 0.79, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Verrica Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Verrica Pharmaceuticals is expected to be smaller as well. At this point, Verrica Pharmaceuticals has a negative expected return of -0.22%. Please make sure to validate Verrica Pharmaceuticals' kurtosis, as well as the relationship between the rate of daily change and price action indicator , to decide if Verrica Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Verrica Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
1 | Jefferies cuts Verrica stock target to 3, maintains Buy rating - Investing.com | 01/06/2025 |
2 | Acquisition by Stalfort John A Iii of 50000 shares of Verrica Pharmaceuticals subject to Rule 16b-3 | 01/17/2025 |
3 | Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcino... | 01/21/2025 |
4 | Molluscum Contagiosum Market Expected to rise, 2034 Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barc... | 02/06/2025 |
5 | Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston | 02/25/2025 |
6 | Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and ... | 03/03/2025 |
7 | Acquisition by Rieger Jayson of 140449 shares of Verrica Pharmaceuticals at 1.335 subject to Rule 16b-3 | 03/07/2025 |
8 | Verrica Pharmaceuticals Inc. Q4 2024 Earnings Call Transcript | 03/12/2025 |
9 | Keeli Husband Elected Vice Chair of Vancouver Regional Construction Associations Young Construction Leaders Executive Committee | 03/13/2025 |
10 | Acquisition by Christopher Hayes of 250000 shares of Verrica Pharmaceuticals at 0.89 subject to Rule 16b-3 | 03/14/2025 |
11 | Disposition of 4315 shares by Christopher Hayes of Verrica Pharmaceuticals at 0.65 subject to Rule 16b-3 | 03/17/2025 |
12 | Verrica Pharmaceuticals chief legal officer sells shares for 2,804 - Investing.com | 03/18/2025 |
| Begin Period Cash Flow | 69.5 M |
Verrica |
Verrica Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 65.00 in Verrica Pharmaceuticals on December 25, 2024 and sell it today you would lose (13.00) from holding Verrica Pharmaceuticals or give up 20.0% of portfolio value over 90 days. Verrica Pharmaceuticals is currently does not generate positive expected returns and assumes 5.7103% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Verrica, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verrica Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verrica Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verrica Pharmaceuticals, and traders can use it to determine the average amount a Verrica Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0384
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VRCA |
Estimated Market Risk
| 5.71 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Verrica Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verrica Pharmaceuticals by adding Verrica Pharmaceuticals to a well-diversified portfolio.
Verrica Pharmaceuticals Fundamentals Growth
Verrica Stock prices reflect investors' perceptions of the future prospects and financial health of Verrica Pharmaceuticals, and Verrica Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verrica Stock performance.
| Return On Equity | -15.47 | ||||
| Return On Asset | -0.6 | ||||
| Operating Margin | (32.93) % | ||||
| Current Valuation | 51.05 M | ||||
| Shares Outstanding | 91.78 M | ||||
| Price To Book | 238.54 X | ||||
| Price To Sales | 6.33 X | ||||
| Revenue | 7.57 M | ||||
| Gross Profit | (7.01 M) | ||||
| EBITDA | (65.9 M) | ||||
| Net Income | (76.58 M) | ||||
| Cash And Equivalents | 14.4 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 45.94 M | ||||
| Debt To Equity | 2.69 % | ||||
| Current Ratio | 1.25 X | ||||
| Book Value Per Share | (0.11) X | ||||
| Cash Flow From Operations | (60.93 M) | ||||
| Earnings Per Share | (1.48) X | ||||
| Market Capitalization | 47.92 M | ||||
| Total Asset | 54.13 M | ||||
| Retained Earnings | (307.03 M) | ||||
| Working Capital | 22.17 M | ||||
About Verrica Pharmaceuticals Performance
By analyzing Verrica Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Verrica Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Verrica Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Verrica Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 485.16 | 509.41 | |
| Return On Tangible Assets | (1.41) | (1.49) | |
| Return On Capital Employed | (2.62) | (2.76) | |
| Return On Assets | (1.41) | (1.49) | |
| Return On Equity | 7.77 | 8.15 |
Things to note about Verrica Pharmaceuticals performance evaluation
Checking the ongoing alerts about Verrica Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verrica Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verrica Pharmaceuticals generated a negative expected return over the last 90 days | |
| Verrica Pharmaceuticals has high historical volatility and very poor performance | |
| Verrica Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Verrica Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.57 M. Net Loss for the year was (76.58 M) with loss before overhead, payroll, taxes, and interest of (7.01 M). | |
| Verrica Pharmaceuticals currently holds about 14.4 M in cash with (60.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Roughly 43.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: Verrica Pharmaceuticals chief legal officer sells shares for 2,804 - Investing.com |
- Analyzing Verrica Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verrica Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Verrica Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verrica Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verrica Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verrica Pharmaceuticals' stock. These opinions can provide insight into Verrica Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Verrica Stock analysis
When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |